A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2015-01, Vol.8, p.669-675 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 675 |
|---|---|
| container_issue | |
| container_start_page | 669 |
| container_title | OncoTargets and therapy |
| container_volume | 8 |
| creator | De Divitiis, Chiara von Arx, Claudia Carbone, Roberto Tatangelo, Fabiana Di Girolamo, Elena Romano, Giovanni Maria Ottaiano, Alessandro de Lutio di Castelguidone, Elisabetta Iaffaioli, Rosario Vincenzo Tafuto, Salvatore |
| description | Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs. |
| doi_str_mv | 10.2147/OTT.S71025 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4386800</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A447930992</galeid><sourcerecordid>A447930992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-33fdc1c347011cd7b4e2d0f20a1474d55420cf50b0fdc392e68866e2780236823</originalsourceid><addsrcrecordid>eNptks1q3DAUhU1padK0mz5AERRKWvBUP7ZlZ1EYQv8gkMVM10IjXY8VZGmQ5Al9or5mlDhNZ6BoIXF1vqPL0S2KtwQvKKn45-v1erHiBNP6WXFKCG_LpmP4-cH5pHgV4w3GTdPS6mVxQuuWtzXmp8WfJVLWOKOkRdJpFKQ23vrtQ8FvbkAlsweUptEHFCDuvIuAbk0aUPSjTD4mmYzLrMxUROer1fIjyoVbsLbUpu8hgEtGJtDIwRQ8OO1VMA7QCEk-4OrR3_coDYCMhWm8QBIpmd8KsPMhvS5e9NJGePO4nxW_vn1dX_4or66__7xcXpWKcZZKxnqtiGIVx4QozTcVUI17imUOqtJ1XVGs-hpvcNaxjkLTtk0DlLeYshwOOyu-zL67aTOCVrn3IK3YBTPK8Ft4acTxjTOD2Pq9qFjbtBhnAzwbaL-HXU4sHsH_qsqPghLc8Yy8n5GttCCM6312VqOJSiyriuf_67r7zhb_UeWlYTTKO-hzbsfAhwNgAGnTEL2dksl_eCz8NAtV8DEG6J86JljcT5jIEybmCcvid4cBPUn_jhS7A0QWz1s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report</title><source>Dove Press Free</source><source>PubMed Central Open Access</source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>De Divitiis, Chiara ; von Arx, Claudia ; Carbone, Roberto ; Tatangelo, Fabiana ; Di Girolamo, Elena ; Romano, Giovanni Maria ; Ottaiano, Alessandro ; de Lutio di Castelguidone, Elisabetta ; Iaffaioli, Rosario Vincenzo ; Tafuto, Salvatore</creator><creatorcontrib>De Divitiis, Chiara ; von Arx, Claudia ; Carbone, Roberto ; Tatangelo, Fabiana ; Di Girolamo, Elena ; Romano, Giovanni Maria ; Ottaiano, Alessandro ; de Lutio di Castelguidone, Elisabetta ; Iaffaioli, Rosario Vincenzo ; Tafuto, Salvatore</creatorcontrib><description>Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S71025</identifier><identifier>PMID: 25878507</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Case Report ; Colon cancer ; Diagnosis ; Drug therapy ; metastatic tumor of the ileum ; neuroendocrine tumor ; octreotide ; Patient outcomes ; radiological tumor response ; Somatostatin ; somatostatin analogs</subject><ispartof>OncoTargets and therapy, 2015-01, Vol.8, p.669-675</ispartof><rights>COPYRIGHT 2015 Dove Medical Press Limited</rights><rights>2015 De Divitiis et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386800/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386800/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3862,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25878507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Divitiis, Chiara</creatorcontrib><creatorcontrib>von Arx, Claudia</creatorcontrib><creatorcontrib>Carbone, Roberto</creatorcontrib><creatorcontrib>Tatangelo, Fabiana</creatorcontrib><creatorcontrib>Di Girolamo, Elena</creatorcontrib><creatorcontrib>Romano, Giovanni Maria</creatorcontrib><creatorcontrib>Ottaiano, Alessandro</creatorcontrib><creatorcontrib>de Lutio di Castelguidone, Elisabetta</creatorcontrib><creatorcontrib>Iaffaioli, Rosario Vincenzo</creatorcontrib><creatorcontrib>Tafuto, Salvatore</creatorcontrib><title>A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.</description><subject>Case Report</subject><subject>Colon cancer</subject><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>metastatic tumor of the ileum</subject><subject>neuroendocrine tumor</subject><subject>octreotide</subject><subject>Patient outcomes</subject><subject>radiological tumor response</subject><subject>Somatostatin</subject><subject>somatostatin analogs</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNptks1q3DAUhU1padK0mz5AERRKWvBUP7ZlZ1EYQv8gkMVM10IjXY8VZGmQ5Al9or5mlDhNZ6BoIXF1vqPL0S2KtwQvKKn45-v1erHiBNP6WXFKCG_LpmP4-cH5pHgV4w3GTdPS6mVxQuuWtzXmp8WfJVLWOKOkRdJpFKQ23vrtQ8FvbkAlsweUptEHFCDuvIuAbk0aUPSjTD4mmYzLrMxUROer1fIjyoVbsLbUpu8hgEtGJtDIwRQ8OO1VMA7QCEk-4OrR3_coDYCMhWm8QBIpmd8KsPMhvS5e9NJGePO4nxW_vn1dX_4or66__7xcXpWKcZZKxnqtiGIVx4QozTcVUI17imUOqtJ1XVGs-hpvcNaxjkLTtk0DlLeYshwOOyu-zL67aTOCVrn3IK3YBTPK8Ft4acTxjTOD2Pq9qFjbtBhnAzwbaL-HXU4sHsH_qsqPghLc8Yy8n5GttCCM6312VqOJSiyriuf_67r7zhb_UeWlYTTKO-hzbsfAhwNgAGnTEL2dksl_eCz8NAtV8DEG6J86JljcT5jIEybmCcvid4cBPUn_jhS7A0QWz1s</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>De Divitiis, Chiara</creator><creator>von Arx, Claudia</creator><creator>Carbone, Roberto</creator><creator>Tatangelo, Fabiana</creator><creator>Di Girolamo, Elena</creator><creator>Romano, Giovanni Maria</creator><creator>Ottaiano, Alessandro</creator><creator>de Lutio di Castelguidone, Elisabetta</creator><creator>Iaffaioli, Rosario Vincenzo</creator><creator>Tafuto, Salvatore</creator><general>Dove Medical Press Limited</general><general>Dove Press</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report</title><author>De Divitiis, Chiara ; von Arx, Claudia ; Carbone, Roberto ; Tatangelo, Fabiana ; Di Girolamo, Elena ; Romano, Giovanni Maria ; Ottaiano, Alessandro ; de Lutio di Castelguidone, Elisabetta ; Iaffaioli, Rosario Vincenzo ; Tafuto, Salvatore</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-33fdc1c347011cd7b4e2d0f20a1474d55420cf50b0fdc392e68866e2780236823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Case Report</topic><topic>Colon cancer</topic><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>metastatic tumor of the ileum</topic><topic>neuroendocrine tumor</topic><topic>octreotide</topic><topic>Patient outcomes</topic><topic>radiological tumor response</topic><topic>Somatostatin</topic><topic>somatostatin analogs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Divitiis, Chiara</creatorcontrib><creatorcontrib>von Arx, Claudia</creatorcontrib><creatorcontrib>Carbone, Roberto</creatorcontrib><creatorcontrib>Tatangelo, Fabiana</creatorcontrib><creatorcontrib>Di Girolamo, Elena</creatorcontrib><creatorcontrib>Romano, Giovanni Maria</creatorcontrib><creatorcontrib>Ottaiano, Alessandro</creatorcontrib><creatorcontrib>de Lutio di Castelguidone, Elisabetta</creatorcontrib><creatorcontrib>Iaffaioli, Rosario Vincenzo</creatorcontrib><creatorcontrib>Tafuto, Salvatore</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Divitiis, Chiara</au><au>von Arx, Claudia</au><au>Carbone, Roberto</au><au>Tatangelo, Fabiana</au><au>Di Girolamo, Elena</au><au>Romano, Giovanni Maria</au><au>Ottaiano, Alessandro</au><au>de Lutio di Castelguidone, Elisabetta</au><au>Iaffaioli, Rosario Vincenzo</au><au>Tafuto, Salvatore</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>8</volume><spage>669</spage><epage>675</epage><pages>669-675</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>25878507</pmid><doi>10.2147/OTT.S71025</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2015-01, Vol.8, p.669-675 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4386800 |
| source | Dove Press Free; PubMed Central Open Access; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Case Report Colon cancer Diagnosis Drug therapy metastatic tumor of the ileum neuroendocrine tumor octreotide Patient outcomes radiological tumor response Somatostatin somatostatin analogs |
| title | A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T05%3A18%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20clinical%20and%20radiological%20objective%20tumor%20response%20with%20somatostatin%20analogs%20(SSA)%20in%20well-differentiated%20neuroendocrine%20metastatic%20tumor%20of%20the%20ileum:%20a%20case%20report&rft.jtitle=OncoTargets%20and%20therapy&rft.au=De%20Divitiis,%20Chiara&rft.date=2015-01-01&rft.volume=8&rft.spage=669&rft.epage=675&rft.pages=669-675&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S71025&rft_dat=%3Cgale_pubme%3EA447930992%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25878507&rft_galeid=A447930992&rfr_iscdi=true |